Teva Tumour Deal, PTV News: Apr 13, 2010

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Teva Tumour Deal, PTV News: Apr 13, 2010
Released on: April 13, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Follow us:
  • Summary
  • Transcript
  • Participants
  • Company
Israeli generics giant in US$ 334M pact with Mersana
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Nikki Watkins
Head, Product & Portfolio Strategy

Nikki is an experienced executive with expertise assisting pharmaceutical companies achieve strategic and financial goals. She has over ten years pharmaceutical industry experience across a variety of roles, including Corporate Finance, R&D Portfolio Management, Commercial Analysis and Consumer Healthcare. Most recently she was Director, Portfolio Consolidation & Analysis at GlaxoSmithKline. Prior to GSK, Nikki worked at PricewaterhouseCoopers, where she qualified as a chartered accountant and gained experience in the insurance and fund management sectors. Nikki has an MA (Hons) in Natural Sciences from the University of Cambridge and is an Associate of the Institute of Chartered Accountants.
Mersana Therapeutics
Mersana Therapeutics is a US-based firm that develops compounds using a biodegradable polymer platform. Its compounds are applicable to the oncology indication field.
Teva Pharmaceutical Industries Ltd. is an international pharmaceutical company headquartered in Petah Tikva, Israel. It specializes in generic and proprietary pharmaceuticals and active pharmaceutical ingredients. It is among the largest generic drug manufacturers in the world and one of the 20 largest pharmaceutical companies worldwide.